Ignite Creation Date:
2024-05-05 @ 5:36 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00488384
Status:
WITHDRAWN
Last Update Posted:
2018-07-19
First Post:
2007-06-19
Brief Title:
Acitretin Plasma Levels Under Hemodialysis
Sponsor:
Günther Hofbauer
Organization:
University of Zurich
Study Overview
Official Title:
Acitretin Plasma Levels Under Hemodialysis
Status:
WITHDRAWN
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
lack of subjects
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year
Detailed Description:
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined
Trial with medicinal product
Trial with medicinal product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None